pubblicazioni full paper mod

Articoli Italian Group for Antiemetic Research (F.Roila, E.Ballatori, V.De Angelis, M.Tonato, A.Del Bavero, G.Ciccarese, O.Martelli et al.): Double-­‐blind, dose-­‐finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-­‐induced acute emesis. Journal of Clinical Oncology, Vol.16, No 9, 1998:2937-­‐2942 1)
2)
C.M. Foggi, O. Martelli: La terapia adiuvante in oncologia
Medicina Ospedaliera, Vol 3 numero 1, Gennaio-­‐Marzo 1999
3)
Pierelli L, Leone G, Cortesi E, Martelli O, Perillo A, Mancuso S, Scambia G. Docetaxel and epirubicin plus G-­‐CSF mobilize hematopoietic progenitors in breast cancer
Ann Oncol. 1999 Dec;10(12):1531-­‐2
4)
Italian Group for Antiemetic Research (F.Roila, E.Ballatori, V.De Angelis, M.Tonato, A.Del Bavero, G.Ciccarese, O.Martelli et al.): Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy New England journal of medicine 342(21), 1554-­‐1559 (2000) may 25
5)
O. Martelli, L Coppola, A.L. De Quarto, M. Palma, R. Sarmiento, C.M. Foggi Fulminant hepatic failure caused by diffuse intrasinusoidal metastatic liver disease: a case report
Tumori 86 (5): 424-­‐427, 2000
A Fattorossi, A Battaglia, L Pierelli, P Mlinconico, L Andreocci, A Perillo, G Ferrandina, O Martelli, A Rughetti, M Nuti, E Cortesi, G Scambia:
Effects of G-­‐CSF and GM-­‐CSF administration on T cell proliferation and phagocyte cell-­‐surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation
Cancer Immunol Immunother, 2001, 49: 641-­‐648
6)
7)
E. Cortesi, O. Martelli, A. Padovani: Ruolo della chemioterapia intraperitoneale Minerva ginecologica vol. 53 suppl 1 n°1, Febbraio 2001
L. De Rosa, M. Lalle, A. Perillo, L. Pierelli, M.G. Salerno, E. Cortesi, O. Martelli, A. Pandolfi, R. Amodeo, L. Marzetti, S. Mancuso, G. Scambia: Docetaxel and epirubicin plus g-­‐csf as mobilizing treatment to support high-­‐dose chemotherapy in breast cancer
Anticancer Research 21: 1367-­‐1370, 2001
9) F De Marinis, F. Nelli, O. Martelli, L. Paoluzzi, M. Rapisarda, A. Petroianni: Docetaxel: suo impiego nel trattamento del carcinoma polmonare nsclc
8)
1
Tumori 87 Suppl 1 (3): S35-­‐36, May-­‐June 2001
10) F. De Marinis, F. Nelli, O. Martelli, L. Paoluzzi, A. Petroianni, M. Rapisarda: Il trattamento nel carcinoma localmente avanzato/metastatico
Rassegna di Patologia dell’apparato Respiratorio, Vol 16/S-­‐5:144-­‐145, June 2001
F. De Marinis, F. Nelli, O. Martelli, L. Pauluzzi, A. Petroianni, M. Rapisarda: Il trattamento nel carcinoma localmente avanzato/metastatico” In Gemcitabina soluzioni terapeutiche personalizzate per il paziente affetto da tumore polmonare non microcitoma Simposio Satelllite -­‐ XXXVI Congresso Nazionale AIPO Rimini Giugno 2001
11)
12) F. De Marinis, F. Nelli, O. Martelli: Il trattamento del carcinoma polmonare non microcitoma avanzato: l’efficacia dei nuovi farmaci In Il cancro del polmone – Il mesotelioma pleurico – Congresso Nazionale FONICAP Cagliari 2001, pp 183-­‐188
13) F De Marinis, O Martelli, F Nelli, L Paoluzzi: Combinazione di chemioterapia con o senza cisplatino. Regimi a due o tre farmaci
Medical International Review Anno V, n 5/2001
F De Marinis, O Martelli, L Paoluzzi: La chemioterapia del microcitoma polmonare: attuali strategie di trattamento
Rassegna di oncologia toracica 16/S-­‐11 Dicembre 2001
14)
M. R. Migliorino, F De Marinis, F Nelli, F Facciolo, M V Immaturo, A Cipri, R Belli, O Ariganello, F Diana, M Di Molfetta, O Martelli: A 3 week schedale of Gemcitabine plus cisplatin as induction chemotherapy for stage III NSCLC
Lung Cancer Vol 35, 2002, 319-­‐327 15)
F. De Marinis, O. Martelli. L. Paoluzzi, F. Nelli, R. Montanaro: Attuali prospettive nel trattamento del carcinoma polmonare a piccole cellule
Volume Educazionale IV Congresso Nazionale AIOM Torino settembre 2002 pp 14-­‐21
16)
F. De Marinis, P F Conte, M Rinaldi, a Chella, A Scanni, E Bongiorni, L Portatone, F. Nelli, O. Martelli et al : Docetaxel in metastatic NSCLC pts who failed previous chemotherapy regimens. A first Italian multicenter phase II study (Taxit 206)
Rassegna di Patologia dell’apparato Respiratorio, Vol 17/5:377-­‐384, Ottobre 2002
17)
F De Marinis, M R Migliorino, L Paoluzzi, L Portalone, o Ariganello, E Cortesi, T Gamucci, S Gasperoni, A Cipri, O Martelli, F Nelli: Phase I/II trial gemcitabine plus cisplatin and etoposide in patients with small-­‐cell lung cancer
Lung Cancer Vol 39, 2003, 331-­‐338
18)
19)
2
F De Marinis, O Martelli, A Mancuso: Combined Chemotherapy and radiation in locally advanced NSCLC Tumori supplemento Vol 2, No 4: S99-­‐102, 2003
20) F De Marinis, O Martelli: Qualità of life in lung cancer. Tumori Supplementi Vol 2, No 1: S19-­‐20, 2003 F De Marinis, O Martelli et al:
Gemcitabine, paclitaxel and cisplatin as induction chemotherapy for pts with biopy-­‐
proven stage III (N2) NSCLC: a phase II multicenter study
Cancer,2003, Vol 98 n 8, 1707-­‐15
22) M Di Maio, F Perrone, C Gallo, RV Iaffaioli et al In List of coauthors O. Martelli. Supportive care in patients with advanced NSCLC. British Journal of Cancer, 2003, 89, 1013-­‐21
21)
F Cappuzzo, F De Marinis, F Nelli, C Calandri, A Maestri, G Benedetti, O Martelli, M Andruccetti, S Bartolini, L Crinò. Phase II study of Gemcitabine-­‐cisplatin-­‐paclitaxel triplet as induction chemotherapy in inoperable, locally advanced NSCLC. Lung Cancer, 2003, 42, 355-­‐361
23)
C Gridelli, A Ardizzoni, T Le Chevalier, C Menegold, F Perrone, N Thatcher, N van Zandwijk, M Di Maio, O Martelli, F De Marinis. Treatment of advance NSCLC patients with ECOG PS 2: results of an European Experts Panel. Annals of Oncology 15, 419-­‐426, 2004
24)
Maione P, Perrone F, Gallo C, Martelli O et al . Treatment quality of life and functional status assesment significantly predict survival of elderly patients with advanced NSCLC receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. Journal of Clinical Oncology, Vol.23, No 28, 2005:6865-­‐72
25)
De Petris L, Migliorino MR, Ceribelli A, Martelli O, Di Molfetta M, Mancuso A, De Santis S, Di Salvia R, De Marinis F. Docetaxel administered every two weeks as second-­‐line chemotherapy for advanced non-­‐
small cell lung cancer: a phase II study. Anticancer Res. 2005 Nov-­‐Dec;25(6C):4713-­‐7
26)
27)
Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, De Marinis F, Ardizzoni A. Short hydration regimen and nephrotoxicity of intermediate to high-­‐dose cisplatin-­‐based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007 Mar-­‐Apr;93(2):138-­‐44. 28)
3
C Gridelli Gallo C et al In List of coauthors O. Martelli. Factorial phase III randomized trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced NSCLC. The gemcitabine coxib in NSCLCC (GECO) study. Lancet Oncol. 2007 Jun;8(6):500-­‐12.
29)
Garassino MC, Farina G, Rossi A, Martelli O, Torri V. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
J Clin Oncol. 2008 May 20;26(15):2600; author reply 2601-­‐2. 30)
Martelli O, Garassino M, Sacchetta S, Caristo R, Zivi A, Cerbone L, Mancuso A. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-­‐Jun;28(3B):1767-­‐71
Garassino MC, Borgonovo K, Rossi A, Mancuso A, Martelli O, Tinazzi A, Di Cosimo S, La Verde N, Sburlati P, Bianchi C, Farina G, Torri V. Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-­‐analysis. Anticancer Res. 2009 Jul;29(7):2691-­‐701
31)
Roila F, Ballatori E, Labianca R, De Braud F, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM). Off-­‐label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey.
Tumori. 2009 Nov-­‐Dec;95(6):647-­‐51
32)
33) Gabriella Farina, Flavia Longo, Olga Martelli, Ida Pavese, Andrea Mancuso et al. Rational treatment and study design of TAILOR: a randomized phase III trial of second-­‐line erlotinib versus docetaxel in the treatment of patients affected by advanced non-­‐small cell lung cancer and with the absence of EGFR mutations. Clin Lung Cancer. 2011 Mar;12(2):138-­‐41
Giuseppe Luigi Banna, Massimo Di Maio, Alessandro Follador, Elena Collovà, Jessica Menisc,Silvia Novello, Emilio Bria, on behalf of ISA Co-­‐ Authors Italian Survey on adjuvant treatment of non-­‐small cell lung cancer (ISA)
Lung Cancer Volume 73, Issue 1 , Pages 78-­‐88, July 2011
34)
Marina C Garassino; Valter Torri; Giovanni Michetti; Monica Lo Dico; Nicla La Verde; Stefania Aglione; Andrea Mancuso; Elisa Gallerani; Domenico Galetta; Olga Martelli et al. Outcomes of Small Cell Lung Cancer patients treated with second-­‐line chemotherapy: A multiinstitutional retrospective analysis.
Lung Cancer Volume 72,Pages 378-­‐383, 2011
35)
4
Novello S, Milella M, Tiseo M, Banna G, Cortinovis D, Di Maio M, Garassino M, Maione P, Martelli O, Vavalà T, Bria E.
Maintenance therapy in NSCLC: why? To whom? Which agent?
J Exp Clin Cancer Res. 2011 May 6;30:50. doi: 10.1186/1756-­‐9966-­‐30-­‐50. Review
36)
37) Farina G, Longo F, Martelli O, Pavese I, Mancuso A, Moscetti L, Labianca R, Bertolini A, Cortesi E, Farris A, Fagnani D, Locatelli MC, Valmadre G, Ardizzoia A, Tomirotti M, Rulli E, Garassino MC, Scanni A.
Rationale for treatment and study design of tailor: a randomized phase III trial of second-­‐
line erlotinib versus docetaxel in the treatment of patients affected by advanced non-­‐
small-­‐cell lung cancer with the absence of epidermal growth factor receptor mutations.
Clin Lung Cancer. 2011 Mar;12(2):138-­‐41. doi: 10.1016/j.cllc.2011.03.008. Epub 2011 Apr 11
38) Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee SM.
Carboplatin-­‐ or cisplatin-­‐based chemotherapy in first-­‐line treatment of small-­‐cell lung cancer: the COCIS meta-­‐analysis of individual patient data
J Clin Oncol. 2012 May 10;30(14):1692-­‐8. doi: 10.1200/JCO.2011.40.4905. Epub 2012 Apr 2. Review.
39) Rossi A, Martelli O, Di Maio M.
Treatment of patients with small-­‐cell lung cancer: from meta-­‐analyses to clinical practice.
Cancer Treat Rev. 2013 Aug;39(5):498-­‐506. doi: 10.1016/j.ctrv.2012.09.006. Epub 2012 Oct 18. Review
40) Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, Bianchi F, Bettini A, Longo F, Moscetti L, Tomirotti M, Marabese M, Ganzinelli M, Lauricella C, Labianca R, Floriani I, Giaccone G, Torri V, Scanni A, Marsoni S; TAILOR trialists.
Erlotinib versus docetaxel as second-­‐line treatment of patients with advanced non-­‐small-­‐
cell lung cancer and wild-­‐type EGFR tumours (TAILOR): a randomised controlled trial.
Lancet Oncol. 2013 Sep;14(10):981-­‐8. Doi:10.1016/S1470-­‐2045(13)70310-­‐3. 2013 Jul 22.
5
Epub